Depo-Provera Meningioma Settlement Signals Pfizer Legal Risk Shift
News about a Depo-Provera meningioma settlement is framed as reshaping Pfizer’s legal risk profile and its investment narrative. While some analysts previously projected strong revenue and earnings by 2029, the settlement coverage and greater reliance on acquisitions rather than organic R&D are presented as highlighting how fragile the optimistic assumptions may be.